EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudieOpen Access · CC BY 4.0

Association of baseline factors with 1-year outcomes in the SB11-ranibizumab equivalence trial: A post hoc analysis

Se Joon Woo, Jin Ah Jung, Taehyung Kim, Inkyung Oh, Mercy Yeeun Kim, Neil M Bressler

Asia-Pacific Journal of Ophthalmology · 2024

DOI: 10.1016/j.apjo.2024.100069 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Asia-Pacific Journal of Ophthalmology, 2024. Verfasst von Se Joon Woo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul National University Bundang Hospital, Republic of Korea. Hauptthemen laut MEDLINE: Ranibizumab, Visual Acuity, Angiogenesis Inhibitors, Intravitreal Injections. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To identify baseline factors associated with 1-year outcomes when treating neovascular age-related macular degeneration (nAMD) with ranibizumab biosimilar SB11 or reference ranibizumab (rRBZ), and to compare efficacy of the two products within subgroups judged to be clinically relevant. DESIGN: Post hoc analysis of a prospective, equivalence phase 3 randomized clinical trial (RCT) METHODS: 705 patients with nAMD were randomized 1:1 to receive SB11 or rRBZ for 48 weeks. Pooled and randomized groups were used to identify baseline factors associated with clinical outcomes at Week 52 using multiple linear regression models. Significant factors identified in regression analyses were confirmed in analyses of variance. Subgroup analyses comparing best-corrected visual acuity (BCVA) changes between SB11 and rRBZ were conducted. RESULTS: 634 (89.9%) participants completed the 52-week visit. Regression analyses showed that younger age, lower BCVA, and smaller total lesion area at baseline were associated with greater BCVA gain at Week 52, while older age, lower BCVA, and thicker central subfield thickness (CST) at baseline were predictors of greater CST reduction in the pooled group. Subgroup analyses demonstrated that BCVA outcomes appeared comparable for the SB11 and rRBZ groups. CONCLUSION: Post hoc analyses of the SB11-rRBZ equivalence study showed that baseline age, BCVA, CST, and total lesion area were prognostic factors for visual or anatomical outcomes of nAMD, while subgroup analyses demonstrated comparable results for SB11 and rRBZ. Collectively, the results appear comparable to similar RCTs of anti-vascular endothelial growth factor reference products for nAMD and strengthen confidence in the biosimilarity of SB11.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanibizumabVisual AcuityAngiogenesis InhibitorsIntravitreal InjectionsHumansMaleFemaleProspective StudiesAgedMiddle AgedBiosimilar PharmaceuticalsWet Macular DegenerationTreatment OutcomeVascular Endothelial Growth Factor ATomography, Optical CoherenceFollow-Up StudiesDouble-Blind MethodAged, 80 and over

Substanzen

RanibizumabAngiogenesis InhibitorsBiosimilar PharmaceuticalsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, Seoul National University Bundang Hospital, Republic of Korea.
  • Samsung Bioepis, Incheon, Republic of Korea.
  • Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: nmboffice@jhmi.edu.

Zitieren

APA

Woo, S. J., Jung, J. A., Kim, T., Oh, I., Kim, M. Y., & Bressler, N. M. (2024). Association of baseline factors with 1-year outcomes in the SB11-ranibizumab equivalence trial: A post hoc analysis. Asia-Pacific Journal of Ophthalmology. https://doi.org/10.1016/j.apjo.2024.100069

Vancouver

Woo SJ, Jung JA, Kim T, Oh I, Kim MY, Bressler NM. Association of baseline factors with 1-year outcomes in the SB11-ranibizumab equivalence trial: A post hoc analysis. Asia-Pacific Journal of Ophthalmology. 2024. doi:10.1016/j.apjo.2024.100069

BibTeX
@article{Woo2024,
  author = {Woo, Se Joon and Jung, Jin Ah and Kim, Taehyung and Oh, Inkyung and Kim, Mercy Yeeun and Bressler, Neil M},
  title = {Association of baseline factors with 1-year outcomes in the SB11-ranibizumab equivalence trial: A post hoc analysis},
  journal = {Asia-Pacific Journal of Ophthalmology},
  year = {2024},
  doi = {10.1016/j.apjo.2024.100069}
}
Kostenlos starten →